LZ1 peptide
LZ1 peptide acts as a Pyruvate kinase inhibitor, antimicrobial agent, and antimalarial agent. LZ1 peptide reduces ATP production and inhibits the malaria parasite Plasmodium falciparum. LZ1 peptide exhibits activity against Plasmodium berghei in mice and reduces parasitemia. LZ1 peptide shows favorable antimicrobial activity against pathogens associated with acne vulgaris. LZ1 peptide possesses anti-inflammatory effects. LZ1 peptide can be used in malaria-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1423743-97-8
- Formel: C113H167N33O15
- Molecular Weight:2227.75
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Parasite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Plasmodium |
LZ1 peptide (1-25 µM; 48 h treatment) potently suppresses asexual blood stage Plasmodium falciparum line 3D7 in vitro with an IC50 of 3.045 µM and shows negligible hemolytic activity against human red blood cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, 8 weeks old, intravenous inoculation of 1.0×106 Plasmodium berghei ANKA-infected erythrocytes)[1]
-
Dosage:4-12 mg/kg (4-day suppression test); 4-12 mg/kg (Rane’s test)
-
Administration:i.v.; daily; 4 days (4-day suppression test); i.v.; daily; 4 days (day 3 to day 6, Rane’s test)
-
Result:Reduced parasitemia to 39% (4 mg/kg), 35% (8 mg/kg), and 24% (12 mg/kg) on day 4 compared to 49% in vehicle group.
Slowed parasitemia growth rate in a dose-dependent manner relative to vehicle group.
Prolonged mouse survival in a dose-dependent manner, with higher doses maintaining survival longer than vehicle group.
Reduced serum IL-6 from ~26 pg/mL to ~10 pg/mL, TNF-α from ~145 pg/mL to ~75 pg/mL, and IFN-γ from ~34 pg/mL to ~15 pg/mL at 12 mg/kg while maintaining serum IL-10 at ~145 pg/mL.
Reduced serum ALT from ~55 µM to ~42 µM, AST from ~400 µM to ~250 µM, and total bilirubin from ~7 µM to ~4 µM at 12 mg/kg relative to vehicle-infected mice.
Chemical Information
-
CAS. Nr. 1423743-97-8
-
Molecular Weight 2227.75
-
Formel C113H167N33O15
-
Sequence
Val-Lys-Arg-Trp-Lys-Lys-Trp-Trp-Arg-Lys-Trp-Lys-Lys-Trp-Val-NH2
-
Sequence Shortening
VKRWKKWWRKWKKWV-NH2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Fang Y, et al. In Vitro and In Vivo Antimalarial Activity of LZ1, a Peptide Derived from Snake Cathelicidin. Toxins. 2019 Jun 30;11(7):379. [Content Brief]
[2]. Salimo ZM, et al. Toxins from Animal Venoms as a Potential Source of Antimalarials: A Comprehensive Review. Toxins. 2023 Jun 03;15(6):375. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
LZ1 peptide Related Classifications
HY-P10338 Related Classifications
Powered by Bioz